GOSS Logo

Gossamer Bio, Inc. (GOSS) 

NASDAQ
Market Cap
$171.79M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
208 of 966
Rank in Industry
128 of 554

Largest Insider Buys in Sector

GOSS Stock Price History Chart

GOSS Stock Performance

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Insider Activity of Gossamer Bio, Inc.

Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.

On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $356,034 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $1M. Giraudo Bryan (COO/CFO) — $118,220. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.

The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.

List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.

2024-06-24SaleChief Medical Officer
1,908
0.0007%
$0.66$1,260+10.16%
2024-06-21PurchasePresident & CEO
372,000
0.2168%
$0.67$250,282+40.00%
2024-06-18PurchaseCOO/CFO
100,000
0.0512%
$0.59$59,110+67.65%
2024-06-17PurchaseChief Commercial Officer
25,000
0.013%
$0.60$15,050+74.72%
2024-03-27SaleEVP, Tech Ops and Admin
6,430
0.0028%
$1.16$7,430-26.60%
2024-03-27SalePresident & CEO
23,172
0.0101%
$1.16$26,773-26.60%
2024-03-27SaleCOO/CFO
6,430
0.0028%
$1.16$7,431-26.60%
2024-03-18SaleChief Medical Officer
4,018
0.0017%
$1.33$5,342-36.08%
2024-03-18SaleEVP, Regulatory Affairs
4,018
0.0017%
$1.33$5,343-36.08%
2023-11-15Purchasedirector
32,000
0.0139%
$0.79$25,213+11.11%
2023-11-13PurchaseCOO/CFO
200,000
0.0795%
$0.56$112,880+40.06%
2023-06-22SaleChief Medical Officer
1,814
0.0018%
$1.29$2,340-34.29%
2023-04-04PurchaseCOO/CFO
55,000
0.0583%
$1.02$56,095+3.45%
2023-03-16SaleChief Medical Officer
7,563
0.0083%
$1.10$8,3040.00%
2023-03-16SaleChief Scientific Officer
6,029
0.0066%
$1.10$6,6200.00%
2023-03-16SaleEVP, Regulatory Affairs
7,564
0.0083%
$1.10$8,3050.00%
2022-10-24SaleChief Medical Officer
4,757
0.0056%
$12.07$57,431-88.94%
2022-10-24SaleChief Scientific Officer
4,876
0.0058%
$12.07$58,868-88.94%
2022-10-24SaleEVP, Regulatory Affairs
4,757
0.0056%
$12.07$57,431-88.94%
2022-07-15PurchasePresident & CEO
138,696
0.099%
$7.21$999,998-79.92%

Insider Historical Profitability

<0.0001%
Hasnain FaheemPresident & CEO
5408073
2.3866%
$0.7642<0.0001%
Christian WaageEVP, Tech Ops and Admin
585934
0.2586%
$0.7643<0.0001%
Giraudo BryanCOO/CFO
480010
0.2118%
$0.7693<0.0001%
Aranda RichardChief Medical Officer
196891
0.0869%
$0.7608
Peterson CarynEVP, Regulatory Affairs
49833
0.022%
$0.7605
Smith Robert Paul JRChief Commercial Officer
25000
0.011%
$0.7610
Omega Fund V, L.P.10 percent owner
6553416
2.892%
$0.7608
Gujrathi SheilaPresident & CEO
4048242
1.7865%
$0.7610<0.0001%
Salter-Cid LuisaChief Scientific Officer
206065
0.0909%
$0.7603
Carter LauraChief Scientific Officer
76263
0.0337%
$0.7616<0.0001%
Milligan Sandradirector
32000
0.0141%
$0.7610
Cox Russell J.director
7200
0.0032%
$0.7610+6.27%
Dupont JakobChief Medical Officer
0
0%
$0.7602

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$18.69M715.84M0%+$00.09
Artal Group S A$15.7M5.8813.31M+10.37%+$1.47M0.07
The Vanguard Group$13.88M5.211.76M+1.1%+$151,217.00<0.0001
Ecor1 Capital Llc$10.85M4.079.2M0%+$00.08
Octagon Capital Advisors LP$10.84M4.069.19M0%+$00.06
Fidelity Investments$9.66M3.628.19M-33.23%-$4.81M<0.01
Arch Venture Management Llc$9.51M3.568.06M0%+$00.47
Millennium Management LLC$7.66M2.876.5M+53.75%+$2.68M0.01
Palo Alto Investors Lp$7.54M2.836.39M+7.26%+$510,806.690.85
Farallon Capital$7.23M2.716.13M0%+$00.05
Silverarc Capital Management Llc$7.23M2.716.13M0%+$00.07
Samsara Biocapital Llc$7.23M2.716.13M0%+$01.13
Eversept Partners LP$7.07M2.655.99M-6.81%-$517,126.740.54
Hillhouse Capital Advisors Ltd$5.87M2.24.97M0%+$00.13
PLATINUM INVESTMENT MANAGEMENT LTD$5.54M2.084.69M-32.5%-$2.67M0.07
Morgan Stanley$5.12M1.924.34M-22.16%-$1.46M<0.0001
Madison Avenue Partners, LP$4.89M1.834.14M-18.08%-$1.08M0.8
Citadel Advisors LLC$4.57M1.713.87M-36.9%-$2.67M<0.01
Deutsche Bank$4.49M1.683.81M0%+$0<0.01
Monashee Investment Management LLC$4.08M1.533.46M0%+$00.35
Ci Private Wealth Llc$3.86M1.453.27M+11.38%+$394,520.06<0.01
ROCK SPRINGS CAPITAL MANAGEMENT, LP$3.86M1.443.27M0%+$00.1
683 Capital Management Llc$3.83M1.443.25M-1.95%-$76,346.000.42
Federated Hermes$3.85M1.393.13M-2.29%-$90,136.000.01
BlackRock$3.65M1.373.09M-8.56%-$341,397.54<0.0001
T. Rowe Price$3.41M1.282.89M-21.76%-$949,152.79<0.0001
Acadian Asset Management$3.23M1.212.74M+51.59%+$1.1M0.01
Goldman Sachs$3.18M1.192.69M-1.18%-$38,097.48<0.01
Opaleye Management Inc$2.88M1.082.44M-18.18%-$639,667.460.64
Laurion Capital Management LP$2.72M1.022.3MNew+$2.72M0.02
Citigroup$2.7M1.012.29M+34.15%+$687,165.82<0.01
Geode Capital Management$2.7M1.012.28M+0.47%+$12,620.59<0.0001
Susquehanna International Group$2.14M0.81.81M+262.61%+$1.55M<0.01
Jacobs Levy Equity Management$1.93M0.721.63M-22.3%-$553,377.480.01
DAFNA Capital Management, LLC$1.66M0.621.41M-4.53%-$78,812.190.04
Driehaus Capital Management LLC$1.61M0.61.37MNew+$1.61M0.02
Charles Schwab$1.48M0.551.25M+2.7%+$38,863.31<0.0001
Marshall Wace$1.45M0.541.23M+21.26%+$254,835.32<0.01
Two Sigma Advisers LP$1.37M0.511.16M+5.44%+$70,682.00<0.01
Sphera Fund$1.21M0.451.03M-23.24%-$366,928.040.01
Two Sigma$954,350.000.36808,771-20.88%-$251,918.26<0.01
State Street$813,316.000.31689,251-3.41%-$28,673.99<0.0001
Renaissance Technologies$792,000.000.3671,600-32.64%-$383,736.74<0.01
Nantahala Capital Management Llc$793,970.000.3672,8560%+$00.04
Qube Research & Technologies$778,428.000.29659,685+188.59%+$508,689.54<0.01
Highbridge Capital Management$705,279.000.26597,694-54.39%-$841,084.040.02
D. E. Shaw & Co.$699,609.000.26592,889+16.97%+$101,481.18<0.01
Hrt Financial Llc$663,000.000.25562,061+4,462.92%+$648,469.84<0.01
Monaco Asset Management Sam$656,080.000.25556,000+98.57%+$325,680.000.3
Td Asset Management Inc$498,267.000.19422,260-16.35%-$97,397.24<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.